Multimodal Biomarkers for Diagnosis and Prognosis in CAA

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

Also called NCT03969732

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03969732
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03969732. Allocation not applicable; no masking; primary purpose diagnostic. Start 2018-09-27 (actual); primary completion 2022-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Multimodal Biomarkers for Diagnosis and Prognosis in CAA
Acronym
CAA
Condition
Cerebral Amyloid Angiopathy
Condition
Intracranial Hemorrhages
Condition
Alzheimer Disease
Intervention (Drug)
1. amyloid PET;2. T807 PET
Lead sponsor
National Taiwan University Hospital (class: other)

Record details

Record id
cardio:ct-nct03969732
Content hash
7bb9eb3380995673e6fdf737584d2c57215f5dcb9151622ee9b9eccd5020f4e6